REDHILL BIOPHAR/S (NASDAQ:RDHL) was upgraded by equities research analysts at WBB Securities from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday, Marketbeat.com reports. The firm currently has a $17.00 price objective on the biotechnology company’s stock. WBB Securities’ price target would indicate a potential upside of 129.73% from the stock’s previous close.
Several other research analysts also recently weighed in on the company. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Ascendiant Capital Markets set a $23.00 price target on REDHILL BIOPHAR/S and gave the stock a “buy” rating in a research note on Monday, July 8th. Finally, Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $17.75.
REDHILL BIOPHAR/S stock opened at $7.40 on Friday. The business has a 50 day moving average price of $7.05. The stock has a market cap of $145.66 million, a price-to-earnings ratio of -4.35 and a beta of 1.40. REDHILL BIOPHAR/S has a 12-month low of $5.13 and a 12-month high of $11.49. The company has a quick ratio of 3.99, a current ratio of 4.09 and a debt-to-equity ratio of 0.06.
A number of hedge funds have recently bought and sold shares of RDHL. Van ECK Associates Corp boosted its position in shares of REDHILL BIOPHAR/S by 42.1% during the 4th quarter. Van ECK Associates Corp now owns 10,787 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 3,195 shares during the last quarter. Geode Capital Management LLC bought a new position in shares of REDHILL BIOPHAR/S during the 4th quarter valued at approximately $73,000. D. E. Shaw & Co. Inc. bought a new position in shares of REDHILL BIOPHAR/S during the 4th quarter valued at approximately $186,000. Sanders Morris Harris LLC bought a new position in shares of REDHILL BIOPHAR/S during the 2nd quarter valued at approximately $330,000. Finally, Menta Capital LLC boosted its position in shares of REDHILL BIOPHAR/S by 9.4% during the 4th quarter. Menta Capital LLC now owns 93,872 shares of the biotechnology company’s stock valued at $521,000 after acquiring an additional 8,087 shares during the last quarter. Institutional investors and hedge funds own 35.48% of the company’s stock.
REDHILL BIOPHAR/S Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
Featured Article: Oversold
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.